Coronary artery disease deaths: why they're falling, and what's still driving risk

Coronary artery disease, the narrowing of the blood vessels that supply the heart with oxygen, remains the leading cause of death worldwide, but the trajectory of that death toll has shifted dramatically since the 1960s. A new study published in JAMA traces just how much progress has been made, and delivers a more sobering finding: that progress has slowed markedly in recent years, even as the biological tools to prevent the disease have never been better.

The basic mechanism behind coronary artery disease is well understood. Fatty deposits, known as plaque, build up gradually inside the arteries that feed the heart muscle. Over years or decades, that plaque can narrow the vessel enough to starve the heart of oxygen during exertion, causing chest pain, or it can rupture suddenly and trigger a blood clot that blocks the artery entirely, causing a heart attack. The disease rarely announces itself early, which is part of why prevention, rather than treatment after the fact, has always mattered so much.

What changed starting in the latter half of the 20th century was a shift in how doctors and public health officials approached the handful of risk factors that drive plaque formation: high blood pressure, high cholesterol, smoking, diabetes and obesity. Widespread use of statins to lower cholesterol, blood pressure medications that became cheaper and more widely prescribed, and a decades-long decline in smoking rates across many wealthy countries combined to drive coronary death rates down substantially from their mid-century peak.

The new study, which pulls together mortality data across a long time horizon, confirms that the decline was not a steady, unbroken line. Progress was fastest in the decades when blood pressure and cholesterol treatment first became widespread, and has slowed considerably more recently. Researchers point to a few plausible explanations: rates of obesity and diabetes have climbed in the same period that blood pressure and cholesterol control improved, effectively offsetting some of those gains, and the easiest wins in tobacco control have largely already been achieved in many of the countries studied.

There's also a geographic and demographic unevenness that a single downward trend line can obscure. The decline in coronary deaths has not touched every population equally. Areas with less consistent access to routine primary care, where the medications that control blood pressure and cholesterol are prescribed and refilled reliably, have not seen the same gains as areas with well-resourced health systems. Researchers involved in the study describe this unevenness as itself a form of missed prevention, arguable proof that existing tools, if delivered more consistently, could still produce further declines.

Diabetes emerges in the research as a particular sticking point. Unlike high cholesterol, which can often be controlled effectively with a single daily pill, diabetes management interacts with weight, diet and often multiple medications at once, and its rising prevalence appears to be quietly counteracting some of the cardiovascular benefit gained elsewhere. Researchers argue that bringing diabetes and obesity trends under better control represents one of the more promising levers left to pull if coronary death rates are going to keep falling at anything like their historical pace.

None of this is an argument that coronary artery disease has become an intractable problem again. The tools that drove decades of improvement, statins, blood pressure medication, smoking cessation support and, more recently, newer classes of drugs that address obesity and metabolic risk directly, remain available and are, if anything, more effective than they were when the decline first began. The concern researchers raise is one of complacency: that decades of genuine progress can create the impression the problem is largely solved, at exactly the moment when sustaining that progress requires renewed attention to a shifting set of risk factors.

For most people, the practical takeaway echoes what cardiologists have said for years, but with a sharper edge given the slowing trend: blood pressure and cholesterol should be checked regularly rather than assumed to be fine, smoking cessation remains one of the single highest-value interventions available, and the newer conversation around managing weight and blood sugar deserves the same seriousness once reserved for cholesterol alone. None of these are new discoveries, but the study's authors argue that the slowdown in progress is itself evidence that awareness has not translated into consistent action across the whole population.

The study's authors are careful to frame their findings as encouragement rather than alarm. A gradual global decline in coronary deaths that took hold across the second half of the 20th century still represents one of preventive medicine's genuine success stories, one built on well-understood biology and inexpensive, widely available treatments rather than any single breakthrough. What the slowing curve suggests is that the story is not finished, and that further gains will likely come less from new drugs than from making sure the ones already available reach the people who still lack consistent access to them.